Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06505265 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT06505265 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 18 participants.
The verdict
NCT06505265, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the effect of multiple doses of orally administered povorcitinib on skin PK and to characterize plasma PK parameters of povorcitinib following multiple doses of orally administered povorcitinib.in healthy participants.
Interventions
- DRUG Povorcitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-08-12 |
| Est. Completion | 2024-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06505265
The ClinicalTrials.gov registry entry for NCT06505265 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Povorcitinib is the first listed.
NCT06505265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06505265 about?
NCT06505265 is a clinical study titled "A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants". The purpose of this study is to measure the effect of multiple doses of orally administered povorcitinib on skin PK and to characterize plasma PK parameters of povorcitinib following multiple doses of orally administered povorcitinib.in healthy participants.
What is the current status of trial NCT06505265?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-08-12. Estimated completion is 2024-09-18.
What interventions are being tested in trial NCT06505265?
The interventions under investigation include: Povorcitinib (DRUG).
Who is sponsoring clinical trial NCT06505265?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.